4SC Hires Experienced Pharmaceutical Manager and Oncology Expert
News Jul 04, 2014
4SC AG has announced that Dr Erich Enghofer has joined 4SC in June 2014 in the newly created position of Executive Vice President Oncology and Haematology thus further strengthening the company's expertise.
The highly experienced pharma manager and oncology expert will primarily advance the strategic marketing of 4SC's main product resminostat in its further development toward market approval in the liver cancer indication.
In this connection, Dr Enghofer will further strengthen 4SC's positioning and products vis-à-vis potential pharmaceutical partners, strategic and clinical opinion leaders and investors, and also support the company in its partnering activities in the field of business development.
Dr Enghofer has more than 30 years of experience in the pharmaceutical industry with a focus on oncology, during which he held various management and executive positions at Bayer, Medac Schering Onkologie, Amgen, Cyanamid-Lederle and Klinge Pharma (now Astellas).
For the last nine years, he was head of the Business Unit Oncology (Haematology-Oncology since 2011) at Bayer HealthCare Deutschland in Leverkusen until May 2014. In this function, he was instrumental, among other things, in the attainment of market approval of the small molecule anti-cancer drug sorafenib (Nexavar®) in the liver cancer indication and the drug's market success in Germany.
Dr Enghofer was a Board member of Deutsche Krebsgesellschaft (DKG, the German Cancer Society) until May 2014 and is a member of various high-profile professional organizations such as the German Association for Haematology and Oncology (DGHO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH) and the American Association for the Advancement of Science (AAAS).
Enno Spillner, CEO of 4SC AG, commented: "We are delighted to have Dr Erich Enghofer, an experienced pharmaceutical manager, joining 4SC. His vast expertise in the field of oncology, especially with the drug sorafenib for treating liver cancer, will further strengthen our team and is most welcome - especially for positioning our compound resminostat as a new potential liver cancer therapy and in our ongoing preparations for a Phase II trial in this indication. Dr Enghofer will also provide crucial support to 4SC in the expansion of a partner network to key opinion leaders and pharmaceutical companies, as well as in the business development process."
Dr Erich Enghofer commented: "I am very much looking forward to working in such a dynamic biotechnology company as 4SC, which has developed a promising and innovative approach for the liver cancer indication with resminostat. I have been following the company's activities and product developments, especially resminostat, for several years now. Liver cancer is the fifth most common type of cancer worldwide and the third most frequent tumour-related cause of death. The number of new cases has been rising sharply over the recent years, giving rise to a high unmet medical need. My goal is to make a contribution to attaining market approval for resminostat so as to make it available for patients as quickly as possible."
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.
Researchers Zoom in on DNA Code Being Read in CellsNews
Scientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life. The mechanism for reading DNA and decoding it to build proteins for their needs is common to all animals and plants, and is often hijacked by cancer. The discovery of exactly how the molecular mechanism works, could open up new approaches to cancer treatment.READ MORE